Summary
The Medicare Payment Advisory Commission (MedPAC) is expected to vote later this week on a series of Medicare Part B reform recommendations. One component of these recommendations will be to implement a Drug Value Program (DVP), a market-oriented alternative to the current average sales price (ASP) system. Ahead of that session, we wanted to share a side-by-side comparison of key design elements for both the DVP and the Competitive Acquisition Program (CAP), the now-defunct predecessor program on which the DVP is based.